Dr Reddy's Labs launches duloxetine capsules
Branded and generic version of duloxetine had US sales of approximately $ 5.04 billion MAT for the most recent twelve months ending in April 2014
 "Dr Reddy's Labs launches duloxetine capsules")
Dr Reddy’s Laboratories has launched duloxetine delayed-release capsules USP 20 mg, 30 mg and 60 mg, a therapeutic equivalent generic version of Cymbalta in the US market on June 26, 2014. Dr Reddy’s ANDA is approved by the United States Food & Drug Administration (USFDA). Cymbalta (duloxetine) is a drug prescribed for neuropathic pain associated with diabetic peripheral neuropathy, depression and anxiety.
According to IMS Health, Cymbalta brand and generic had US sales of approximately $ 5.04 billion MAT for the most recent twelve months ending in April 2014.
According to IMS Health, Cymbalta brand and generic had US sales of approximately $ 5.04 billion MAT for the most recent twelve months ending in April 2014.